Positive Results in the EMBOLD study of relutrigine showed a 53% placebo-adjusted reduction in seizures (p < 0.0002), 66% increase in motor ...

Seven months ago, independent clinical trial observers peeked at interim data for Praxis Precision Medicines’ essential tremor drug and recommended stopping the Phase 3 studies. Praxis kept going. On ...

Clear recognition of high unmet need and urgency for the SCN2A community and plausibility of the mechanism of elsunersen . FDA agreed to proposed changes to the EMBRAVE3 trial des ...

Praxis Precision Medicines shares shot skyward Friday after the company stopped an epilepsy study early due to strong effectiveness.

I maintain a Hold rating on Praxis Precision Medicines, Inc., driven by positive open-label Radiant data for vormatrigine in epilepsy but tempered by clinical risks. Vormatrigine achieved a 56.3% ...

Praxis Precision Medicines stock remains a "Hold" despite a setback with interim analysis done by the IDMC; The company continues on with full data from both Study 1 and Study 2 in Q3 of 2025. The ...

Tuesday, Praxis Precision Medicines Inc . (NASDAQ:PRAX) shares received a boost as Truist Securities increased its price target for the company to $175 from $150, while maintaining a Buy rating. The ...

BOSTON, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for ...

BOSTON, May 09, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for ...

Having already claimed a win for the phase 2 study of its seizure drug, Praxis Precision Medicines is hoping fresh efficacy data will form the backbone of an approval application for the sodium ...